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Axial functionalisation of photoactive diazido
platinum(IV) anticancer complexes†
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Mono-axial functionalised octahedral diazido Pt(IV) complexes trans,trans,trans-[Pt(py)2(N3)2(OR1)(OR2)]
(OR1 = OH and OR2 = anticancer agent coumarin-3 carboxylate (cou, 2a), pyruvate dehydrogenase
kinase (PDK) inhibitors 4-phenylbutyrate (PhB, 2b) or dichloroacetate (DCA, 2c)), and their di-axial func-
tionalised analogues with OR1 = DCA and OR2 = cou (3a), PhB (3b), or DCA (3c) have been synthesised
and characterised, including the X-ray crystal structures of complexes 2a, 3a, 3b and 3c. These complexes
exhibit dark stability and have the potential to generate cytotoxic Pt(II) species and free radicals selectively
in cancer cells when irradiated. Mono-functionalised complexes 2a–2c showed higher aqueous solubility
and more negative reduction potentials. Mono- and di-functionalised complexes displayed higher photo-
cytotoxicity with blue light (1 h, 465 nm, 4.8 mW cm−2) than the parent dihydroxido complex 1 (OR1 =
OR2 = OH) in A2780 human ovarian (IC50 0.9–2.9 µM for 2a–2c; 0.11–0.39 µM for 3a–3c) and
A549 human lung cancer cells (5.4–7.8 µM for 2a–2c; 1.2–2.6 µM for 3a–3c) with satisfactory dark stabi-
lity. Notably, no apparent dark cytotoxicity was observed in healthy lung MRC-5 fibroblasts for all com-
plexes (IC50 > 20 µM). Significantly higher platinum cellular accumulation and photo-generated ROS
levels were observed for the di-functionalised complexes compared with their mono-functionalised ana-
logues when cancer cells were treated under the same concentrations.
Introduction
Octahedral Pt(IV) complexes with low-spin 5d6 configurations
are generally very stable, but can often be activated by bio-
reductants in vivo (e.g. GSH, ascorbic acid, and cysteine resi-
dues) to give the corresponding more reactive Pt(II) drugs.1–3
The Pt(IV) drugs iproplatin,4,5 ormaplatin,6 satraplatin7 and
LA-128 have entered clinical trials, but none has yet received
clinical approval.9 A problem for Pt(IV) drugs, which are acti-
vated by chemical reduction in the body, is that the extent and
cell selectivity of activation are difficult to control since they
rely on natural processes.2,3 The use of localised light to
control the activation of Pt(IV) prodrugs might overcome this
problem.10–12
In contrast to Pt(IV) complexes which exert their cytotoxicity
via chemical reduction, photoactive Pt(IV) complexes require
higher dark stability and resistance to bio-reductants to guar-
antee that these prodrugs reach cancer cells and can be selec-
tively photoactivated there.2,10–14 Trans,trans,trans-[Pt
(py)2(N3)2(OH)2] (1) is a promising photoactive diazido Pt(IV)
complexes that exhibits high dark stability and photoactivation
upon visible light irradiation.15 The axial ligands of Pt(IV) com-
plexes can be released during reduction, and greatly affect the
reduction potential of Pt(IV).16,17 In general, Pt(IV) complexes with
axial hydroxide ligands exhibit higher dark stability than those
with other axial ligands.18,19 However, Pt(IV) prodrugs with bio-
active axial ligands can selectively target cancer cells and attack
several cellular components at the same time, providing a multi-
targeted mechanism of action, which can result in enhanced anti-
cancer potency and circumvention of cisplatin resistance.3,20,21
Here, conjugates of 1 with various anticancer drugs and cancer-
targeting vectors as axial substituents have been investigated.
Related reported complexes mostly have only one axial position
derivatised and retain one hydroxide ligand to stabilise the Pt(IV)
and increase aqueous solubility.10 Only one di-functionalised
photoactive trans-diazido Pt(IV) complex with different functional
ligands appears to have been reported so far.22
The formation of esters via reactions of carboxylic acids
and an axial hydroxide ligand in Pt(IV) complexes is a promis-
ing strategy for the development of multifunctional drugs.3,10
In this work, anticancer agent coumarin-3 carboxylate (cou),
pyruvate dehydrogenase kinase (PDK) inhibitor 4-phenylbuty-
rate (PhB) and dichloroacetate (DCA) were conjugated to
diazido Pt(IV) complex 1 to generate mono-functionalised com-
plexes 2a–2c, which were further modified with a DCA ligand
to give di-functionalised complexes 3a–3c (Scheme 1).
†Electronic supplementary information (ESI) available: Experimental section,
NMR, UV-vis, and LC-MS spectra. CCDC 2003123–2003126. For ESI and crystallo-
graphic data in CIF or other electronic format see DOI: 10.1039/d0qi00685h
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Coumarin and derivatives containing a benzopyrone
target a number of pathways in cancer cells (e.g. kinase
inhibition, cell cycle arrest, and angiogenesis inhibition) and
have been widely used as anticancer agents.23–27 Coumarin
derivatives can act as an antenna for light-harvesting when
conjugated to metal complexes, and therefore enhance the
fluorescence quantum yield and lengthen their emission life-
times.28 PDK inhibitor PhB can suppress aerobic
glycolysis, reverse the Warburg effect, and eventually kill
cancer cells.29 In addition, PhB also acts as a weak extracellular
histone deacetylase (HDAC) inhibitor.29,30 DCA is frequently
tagged on to anticancer metal complexes for its
mitochondrial targeting and PDK-inhibiting properties.29,31
The di-DCA Pt(IV) complex mitaplatin is activated by chemical
reduction and then (i) liberates Pt(II) species that can attack
nuclear DNA and (ii) DCA that can attack mitochondria,
giving rise to notable selectivity towards cancer cells.31 The
combination of DCA and other functional substituents in a
Pt(IV) complex can result in significantly improved
cytotoxicity.3,22,29,31,32
Photoactive complexes 2a–2c and 3a–3c with the general
formula trans,trans,trans-[Pt(py)2(N3)2(OR1)(OR2)] have been
synthesised and characterised, and the X-ray crystal structures
of 2a, 3a, 3b and 3c were determined. The reduction poten-
tials, dark stability and photodecomposition, photoreactions
with 5′-GMP, photocytotoxicity and cellular accumulation are
compared between mono-functionalised 2a–2c, di-functiona-
lised 3a–3c, and unfunctionalised parent complex 1.
Results and discussion
Synthesis and characterisation
The synthetic routes for photoactive Pt(IV) complexes 2a–2c
and 3a–3c are summarised in Scheme 1. Mono-functionalised
complexes 2a and 2b were obtained by combining parent
complex 1 with the corresponding acid using TBTU as a coup-
ling agent. The bi-functionalised complexes 3a and 3b were
synthesised by stirring 2a and 2b with dichloroacetic anhy-
dride, respectively, while 2c and 3c were made by reacting 1
directly with dichloroacetic anhydride. Complexes 2a–2c and
3a–3c are air-stable at 298 K in the solid state in the dark. Dark
stability was observed for 2a–2c in RPMI-1640 cell culture
medium by UV-vis spectroscopy (Fig. S1, ESI†). Complexes 3a–
3c showed poor aqueous solubility, but were stable in DMSO
(Fig. S1, ESI†). The dark stability of complexes 2a and 3a in the
presence of 2 mM GSH was confirmed by UV-vis spectroscopy
(Fig. S2, ESI†). All complexes were characterised by ESI-HR-MS,
NMR and UV-vis spectroscopy and their purity was determined
by HPLC as >95% (Fig. S3–S16, ESI†).
All observed m/z values and the isotopic mass distribution
patterns for Pt and Cl match well with calculated HR-MS
spectra (Fig. S4, ESI†). All 1H and 13C NMR spectra are in
agreement with the proposed structures for the complexes
(Fig. S5–16, ESI†). The Pt-coordinated pyridine can be identi-
fied by 1H NMR doublets with 195Pt satellites at ca. 9.0 ppm,
and the triplets at ca. 8.1 and 7.7 ppm and by 13C NMR reso-
nances at ca. 150, 142 and 126 ppm assignable to the α, γ and
β C–H groups, respectively, of pyridine. The electronic absorp-
tion spectra of complexes 2a–2c and 3a–3c are similar to that
of parent complex 1 with a maximum absorption band at ca.
300 nm (ε ca. 17 000 M−1 cm−1) assignable to LMCT (N3 → Pt)
transitions. The extinction coefficients of 2a and 3a at ca.
300 nm (ε ca. 31 000 M−1 cm−1) are much higher due to the
presence of the coumarin moiety.
X-ray crystallography
Crystals of complexes 2a, 3a, 3b and 3c suitable for X-ray diffr-
action studies were obtained through evaporation, or diffusion
of diethyl ether into DCM/MeOH solutions. The perspective
drawings of complexes 2a and 3a–3c are shown in Fig. 1. The
crystallographic data are summarised in Table S1 (ESI†) and
selected bond distances and angles are listed in Tables 1 and
S2 (ESI†). Complexes 2a, 3b and 3c crystallised in the triclinic
P1ˉ space group, while complex 3a crystallised in the trigonal
R3ˉ space group. These complexes show similarities in the
equatorial plane defined by four nitrogen atoms, two from the
trans pyridine molecules and two from the trans azide anions,
and resemble typical equatorial planes in their analogues.15
With azide-Pt bond angles of ca. 116°, the plane contains only
the bound nitrogens of the azide ligands with the remainder
of the azide ligands projected out on opposite faces of the
plane. The difference lies in the axial ligands. Complex 2a is
mono-functionalised with an O-bound coumarin-3 carboxylate
and a trans hydroxide ligand (O–Pt–O bond angle of 175.13
(6)°), which forms a moderately strong hydrogen bond with
Scheme 1 Synthetic routes for photoactive diazido Pt(IV) complexes
2a–2c and 3a–3c. (i) cou/PhB acid, TBTU, DIPEA, DMF, N2, RT, over-
night; (ii) DCA anhydride, DMF, N2, RT, overnight.
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OH in an adjacent molecule (O3–H3B⋯O3, Table S3, ESI†).
For complex 3c with two dichloroacetate ligands, the Pt sits on
a crystallographic inversion centre, while complexes 3a and 3b
exhibit distortions from ideal octahedral geometry, with trans
O–Pt–O bond angles smaller than 180° (171.97(12)° for 3a, and
178.76(10)° for 3b). The Pt–O bond distance is 2.005(3) Å for
the coumarin-3 carboxylic acetate in complex 3a and 1.992(3) Å
for 4-phenylbutyrate in 3b. These distances are slightly shorter
than the Pt–O bond lengths for their respective dichloroacetate
ligands (2.020(3) and 2.016(3) Å).
Cyclic voltammetry
Cyclic voltammograms for 1, 2a and 3a were acquired in the
potential range −1.8–0.0 V in DMF at 298 K, using 0.1 M
NBu4PF6 as supporting electrolyte (Fig. 2). An irreversible
reduction wave assigned to PtIV/PtII was observed with Epc of
−1.699, −1.285 and −0.886 V for 1, 2a and 3a, respectively. It is
notable that Pt(IV) complexes with the more unmodified
hydroxide axial ligands (OH) exhibit more negative reduction
potentials, consistent with the ability of axial hydroxide to
stabilise these Pt(IV) complexes.18,19 The irreversible reduction
waves suggest that these complexes release ligands during
reduction, as observed upon irradiation where cytotoxic
species are released as a result of photoreduction.
Photoactivation and radical formation
The photodecomposition of complexes 2a–2c in RPMI-1640
cell culture medium with 5% DMSO (used for solubilisation
during cytotoxicity screening) and 3a–3c in DMSO was moni-
tored by UV-vis spectroscopy at different time intervals after
irradiation with blue light (420 nm) at 298 K (Fig. 3, S17 and
S18, ESI†). Fig. 3 shows the decrease in absorbance maximum
of complex 2a at 298 nm, assigned as a LMCT band (N3 → Pt).
The decrease was rapid over the first 15 min and showed no
significant further change after 30 min, suggesting release of
the azide ligands. Similar results were obtained using mono-
functionalised 2b and 2c (Fig. S17, ESI†), consistent with pre-
viously published data for complex 1.15 Notably, the photo-
decomposition of di-functionalised 3a–3c in DMSO was com-
plete in 10 min with blue light irradiation (Fig. S18, ESI†). The
incorporation of the coumarin-3 carboxylate provides the
possibility of using complex 2a in fluorescence emission spec-
troscopic studies. Even though coumarin-3 carboxylic acid
Fig. 1 X-ray crystal structures of mono-functionalised 2a and di-functionalised 3a, 3b, and 3c, with thermal ellipsoids drawn at 50% probability
level.
Table 1 Selected bond lengths (Å) and bond angles (°) for 2a and 3a
Complex 2a Complex 3a
Pt1–O3 1.9753(17) Pt1–O19 2.020(3)
Pt1–N25 2.049(2) Pt1–N13 2.045(4)
Pt1–N28 2.044(2) Pt1–N16 2.058(4)
Pt1–O1 2.0289(16) Pt1–O24 2.005(3)
Pt1–N13 2.033(2) Pt1–N1 2.040(3)
Pt1–N19 2.025(2) Pt1–N7 2.028(3)
N25–N26 1.212(3) N13–N14 1.211(5)
N26–N27 1.139(3) N14–N15 1.147(5)
N28–N29 1.209(3) N16–N17 1.222(5)
N29–N30 1.147(3) N17–N18 1.148(6)
O1–Pt1–O3 175.13(6) O19–Pt1–O24 171.97(12)
N13–Pt1–N19 178.33(8) N1–Pt1–N7 179.26(15)
N25–Pt1–N28 179.07(8) N13–Pt1–N16 178.49(14)
N26–N25–Pt1 116.89(17) N14–N13–Pt1 116.0(3)
N25–N26–N27 174.3(3) N13–N14–N15 175.2(5)
N29–N28–Pt1 117.37(18) N17–N16–Pt1 114.9(3)
N28–N29–N30 174.6(3) N16–N17–N18 175.2(4)
Cl23–C21–Cl22 112.1(3)
Fig. 2 Cyclic voltammograms for complexes 1, 2a and 3a (1 mM) in 0.1
M NBu4PF6-DMF (deaerated under N2).
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exhibited no apparent fluorescence in aqueous solution with
excitation at 405 nm, it can exhibit switched-on blue fluo-
rescence (ca. 450 nm) in the presence of OH•, owing to the
generation of fluorescent 7-hydroxycoumarin-3 carboxylic acid
(pKa = 1.98).
33 While no apparent fluorescence was observed
before irradiation, 2a exhibited emission centred at ca. 440 nm
after irradiation with blue light (420 nm, 20 min) at 298 K
(Fig. S19, ESI†). This emission can be attributed to the for-
mation of 7-hydroxycoumarin-3 carboxylate from coumarin-3
carboxylate and OH• radicals as photoproducts of 2a which
contains coumarin-3 carboxylate and hydroxide ligands. In
contrast, no emission was detected for 3a (which has no
hydroxide ligands) under the same irradiation conditions.
However, 7-hydroxycoumarin-3 carboxylate was not detected by
LC-MS (Table S4, ESI†).
The photoproducts from complex 2a irradiated in aqueous
solution were investigated by LC-MS. Only a HPLC peak
assigned to 2a was observed before irradiation, indicating the
high purity of the complex (>99%). This peak disappeared
within 20 min of irradiation with blue light (420 nm, Fig. S20,
ESI†). The peak assigned to {PtIV(py)2(N3)(OH)(cou)}
+ (601.18
m/z, peak f in Fig. S20 and Table S4, ESI†) increased in inten-
sity up to 5 min, and thereafter decreased in 5–30 min with a
concomitant increase in intensity of peaks for the photo-
products [2{PtII(py)(OH)2(HCOO)} + 3Na]
+ (774.99 m/z, a),
{PtII(py)(cou)(CH3CN)2}
+ (545.10 m/z, b), {PtIII(py)2(HCOO)
(N3)}
+ (440.07 m/z, c), {PtII(py)2(N3)(CH3CN)}
+ (436.08 m/z, d),
[{PtII(py)2(N3)2} + Na]
+ (460.08 m/z, g), [{PtII(py)(cou)(HCOO)
(N3)} + 2H]
+ (552.05 m/z, h), and coumarin-3 carboxylic acid
(191.29 m/z, e Fig. S20 and Table S4, ESI†). The formic acid
and acetonitrile ligands arise from the mobile phase in
LC-MS. The photodecomposition of 2a is complicated. In
general, one azide ligand appears to be released from Pt(IV)
complexes first to form {PtIV(py)2(N3)(OH)(cou)}
+ (601.18 m/z,
f ), which can then liberate the other azide or the axial ligand
(OH or cou) to form Pt(II) species. When the irradiation time
increased, some Pt(II) species underwent further release of
both axial ligands.
Reactive radicals released by photo-irradiated complex 2a in
aqueous solution were detected by EPR using the spin-trap 5,5-
dimethyl-1-pyrroline-N-oxide (DMPO, Fig. 4). The EPR spectra
for 2a showed no signal in the absence of irradiation, while a
1 : 2 : 2 : 1 quartet of triplet peaks assigned as DMPO-N3
• and a
quartet signal as DMPO-OH• were detected after irradiation
(463 nm). Hence the EPR results suggest the formation of OH•
and N3
• radicals after irradiation (50 min).
Photoreaction with 5′-GMP (guanosine 5′-monophosphate)
The photoreaction was carried out by irradiating an aqueous
solution of complex 2a (30 μM) in the presence of 2 mol equiv.
of 5′-GMP with blue light (420 nm) at 310 K without prior incu-
bation, and was monitored by LC-MS at different time intervals
(Fig. S21, ESI†). The major photoproduct of the reaction was
assigned as {PtII(CH3CN)(py)2(GMP-H)}
+ (756.16 m/z, G1),
which increased in concentration with the irradiation time. Pt-
GMP adducts {PtII(HCOO)(py)2(GMP)}
+ (762.10 m/z, G2) and
{PtII(N3)(py)2(GMP)}
+ (758.16 m/z, G3) were also detected
(formic acid and acetonitrile arise from the HPLC mobile
phase). Notably, the major Pt-GMP adducts generated by 2a
are the same as those for 1 and its derivatives, indicating that
the axial substituents do not affect the interaction between
guanine and the platinum centre upon irradiation.15,34
Photocytotoxicity and cellular accumulation studies
The photocytotoxicity of complexes 2a–2c and 3a–3c was deter-
mined in A2780 ovarian and A549 lung cancer cells, after 1 h
drug incubation, 1 h irradiation (465 nm, 4.8 mW cm−2) and
Fig. 3 Photochemical decomposition of mono-functionalised Pt(IV)
complex 2a (50 µM) in phenol red-free RPMI-1640 cell culture medium
with 5% DMSO (v/v) upon irradiation with blue light (420 nm, 1 h) at
298 K.
Fig. 4 Observed (black) and simulated (red) EPR spectra of mono-func-
tionalised complex 2a (2.5 mM) with an axial coumarin in aqueous solu-
tion with 5% DMSO showing the formation of DMPO-N3
• and
DMPO-OH• adducts after irradiation (463 nm). The experimental trace is
the accumulation of 300 scans with continuous irradiation (465 nm,
50 min). Parameters for simulation: DMPO-N3
• (g = 2.00595, aNNO =
1.43 mT, aHβ = 1.45 mT, and a
N
Nα = 0.29 mT); DMPO-OH
• (g = 2.00592,
aNNO = 1.43 mT, and a
H
β = 1.45 mT).
34
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24 h recovery (Table 2). Their dark cytotoxicity was also deter-
mined after 2 h incubation and 24 h recovery in A2780 and
A549 cancer cells, as well as MRC-5 normal lung fibroblasts for
comparison. Due to the poor aqueous solubility of these com-
pounds, DMSO was used to facilitate their dissolution. Even
though DMSO is a strong ligand for Pt(II), no Pt-DMSO adduct
was detected during irradiation (Table S4, ESI†). Also, due to
the low DMSO concentration (<0.5%) and short incubation
time (1 h in the dark and 1 h irradiation), DMSO did not
exhibit significant effects on the cytotoxicity of these
complexes.
The IC50 values determined by the sulforhodamine B (SRB)
colorimetric assay are summarised in Table 2. Mono-functio-
nalised Pt(IV) complexes 2a–2c were non-toxic in the dark with
IC50 values >100 μM, while di-functionalised Pt(IV) complexes
3a–3c were cytotoxic to A2780 ovarian cancer in the dark (IC50
values of 1.3–1.9 µM), but relatively non-toxic to A549 lung
cancer and normal MRC-5 lung cells (IC50 values >20 μM). The
selective toxicity towards ovarian cancer cells might be an
advantage for use of these complexes as phototherapeutic pro-
drugs for topical application, especially considering their low
cytotoxicity towards normal MRC-5 cells.
The photocytotoxicity of mono-functionalised complexes
2a–2c in A2780 ovarian cancer cells (IC50 values of 0.9–2.9 µM)
was >2.4× higher than that of unfunctionalised 1 (7.1 µM), and
in A549 lung cancer cells (IC50 values of 5.4–7.8 µM) was >6.6×
higher than that of 1 (51.9 µM). Moreover, di-functionalised
Pt(IV) complexes 3a–3c (IC50 values of 0.11–0.39 µM for A2780;
1.2–2.6 µM for A549) showed >3× enhanced photocytotoxicity
compared with their mono-functionalised analogues 2a–2c in
both of the cancer cell lines tested. Notably, similar photocyto-
toxicity indices (PI) were found for mono-functionalised 2a–2c
and di-functionalised 3a–3c in lung A549 cancer cells
(Table 2), while >2–17× higher PI values were determined for
2a–2c compared to their corresponding di-functionalised ana-
logues in ovarian A2780 cancer cells, although 3a–3c showed
significantly higher photocytotoxicity in A2780 cells.
The cellular accumulation of complexes 2a–2c and 3a–3c
was determined in A2780 ovarian cancer cells, and that of 2a
and 3a also for A549 lung cancer cells at the same concen-
tration (2 μM, Table 3). Mono-functionalised complexes exhibi-
ted >19× higher accumulation than unfunctionalised 1, and
significantly higher cellular accumulation was observed for di-
functionalised complexes compared to the corresponding
mono-functionalised analogues (ca. 3–18×, Table 3). The lipo-
philicity (based on the reversed-phase HPLC retention time)
has a major influence on cellular Pt accumulation, following
the trend: di-functionalised 3a–3c > mono-functionalised 2a–
2c > unfunctionalised 1 (Table 3). This trend matches that for
photocytotoxicity well: di-functionalised 3a–3c > mono-functio-
nalised 2a–2c > unfunctionalised 1. These results suggest that
the extent of cellular accumulation of these Pt(IV) prodrugs
plays an important role in their antiproliferative potency.
Cellular ROS generation
Since mitochondrial-targeting DCA can suppress aerobic gly-
colysis and increase mitochondrial oxidative phosphorylation
and ROS production,35 the cellular ROS levels in A549 cells
treated with mono-DCA complex 2c or di-DCA complex 3c were
determined by the DCFH-DA assay (Fig. 5). DCFH-DA is a cell-
permeable non-fluorescent probe that is converted to the
highly fluorescent dye DCF upon oxidation by ROS in cells.36
As expected, A549 lung cancer cells treated with 3c (2 μM)
exhibited intense green fluorescence after 1 h irradiation
(465 nm) indicative of ROS generation, while no fluorescence
Table 3 Cellular accumulation of Pt in A2780 cells and A549 cells after
exposure to unfunctionalised 1, mono- and di-functionalised complexes
2a–2c and 3a–3c, respectively (2 μM, 1 h, in the dark)
Cell Complex Pta (ng per 106 cells)
A549 1 0.51 ± 0.03***
2a 9.8 ± 2.1*
3a 36.1 ± 1.5***
A2780 1 0.16 ± 0.02*
2a 6.2 ± 0.5**
2b 3.5 ± 0.4***
2c 10.8 ± 0.3***
3a 90.9 ± 12.0***
3b 61.4 ± 5.0***
3c 53.8 ± 1.9***
a All data were determined from triplicate samples and their statistical
significance compared to untreated cells evaluated by a two-tail t-test
with unequal variances. *p < 0.05, **p < 0.01, ***p < 0.005.
Table 2 IC50 values and photocytotoxicity indices (PI) for mono-func-
tionalised complexes 2a–2c and di-functionalised 3a–3c for A2780
ovarian and A549 lung cancer cells, and MRC-5 normal lung fibroblasts
(1 h incubation, 1 h irradiation (465 nm), followed by 24 h recovery).





2a Darkb >100 >100 >100
Irrad 2.9 ± 0.2 7.8 ± 0.1
PI >34 >12
2b Dark >100 >100 >100
Irrad 0.92 ± 0.07 5.44 ± 0.05
PI >108 >18
2c Dark >100 >100 >100
Irrad 1.2 ± 0.2 6.6 ± 1.1
PI >83 >15
3a Dark 1.9 ± 0.1 >50 >50
Irrad 0.11 ± 0.02 2.6 ± 0.3
PI 17.3 >19
3b Dark 1.3 ± 0.2 >20 >20
Irrad 0.15 ± 0.01 1.2 ± 0.1
PI 8.7 >16
3c Dark 1.9 ± 0.3 >20 >20
Irrad 0.39 ± 0.01 1.9 ± 0.1
PI 4.9 >10
1 Dark >100 >100 >100
Irrad 7.1 ± 0.4 51.9 ± 2.5
PI >14 >1.9
a Each value is the mean of two independent experiments ± standard
deviation. bDark cytotoxicity was determined after 2 h incubation and
24 h recovery.
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was observed in the dark. In contrast, cells treated with 2c
(2 μM) displayed much less intense fluorescence after
irradiation and again no fluorescence in the dark. These
results indicate that a lower level of ROS was induced by
mono-functionalised 2c compared to its di-functionalised ana-
logue 3c, which correlates with its lower photocytotoxicity and
cellular accumulation.
Conclusions
Here we have synthesised and characterised six novel photo-
active trans-diazido Pt(IV) dipyridine complexes, which differ in
the presence of either one axial hydroxide ligand (mono-func-
tionalised complexes 2a–2c, with cou, PhB or DCA as an axial
ligand, respectively), or no axial hydroxide ligands (di-functio-
nalised complexes 3a–3c with DCA as the second axial ligand).
The X-ray crystal structures of complexes 2a and 3a–3c show a
typical octahedral structure slightly distorted by the asym-
metric axial ligands. These complexes are photoactive, gene-
rate Pt(II) species which bind to 5′-GMP as monitored by
LC-MS, and release azidyl and hydroxyl radicals as detected by
EPR. Both axial ligands can be released from these complexes
upon irradiation. However, mono-functionalised and di-func-
tionalised complexes displayed significant differences in their
photochemical and photobiological properties as summarised
in Table 4.
Notably, mono-functionalised complexes 2a–2c with one
hydroxide ligand show higher aqueous solubility, and more
negative reduction potentials. In contrast, due to the replace-
ment of hydroxide with a lipophilic dichloroacetate ligand, di-
functionalised complexes 3a–3c exhibited much reduced
aqueous solubility. Significantly higher cellular Pt accumu-
lation (ca. 3–18×) and photo-induced cellular ROS levels were
observed for di-functionalised complexes compared with their
mono-functionalised analogues when cells were treated with
complexes at the same concentration. As a result, higher photo-
cytotoxicity (>3×) of di-functionalised complexes 3a–3c com-
pared with 2a–2c and 1 in cancer cells was found. Mono-func-
tionalised complexes 2a–2c also showed improved photocyto-
toxicity (>2.4× in A2780; >6.6× in A549) compared to unfunctio-
nalised 1 and were non-toxic in the dark (IC50 values >100 µM).
Notably, all of these complexes showed a higher photocytotoxi-
city and cellular accumulation in A2780 ovarian cancer cells
compared to A549 lung cancer cells, and low cytotoxicity
towards normal MRC-5 cells. Mono-functionalised complexes
exhibited higher photoselectivity towards A2780 cells due to
their low dark cytotoxicity, but di-functionalised complexes
exhibited a selectivity towards A2780 cells both in the dark and
upon irradiation with extremely high cellular accumulation and
high potency (low-dose required). Thus, these di-functionalised
complexes are promising candidates as clinical prodrugs to
treat ovarian cancer locally by phototherapy.
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Table 4 Comparison between mono- and di-functionalised complexes






Aqueous solubility Good Poor
Reduction potential More negative Less negative
Dark cytotoxicity Similar to 1 (low) Higher
Photo-cytotoxicity Higher than 1 Higher than 2a–2c
Cellular
accumulation
Higher than 1 Much higher than 2a–2c
ROS generation Low High
Research Article Inorganic Chemistry Frontiers





















































































HR-MS data collection and Ian J. Hands-Portman for confocal
microscopy training.
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